A PYMNTS Company

EU/US: Fresenius in talks to buy Akorn

By  |  April 9, 2017

Fresenius, Europe’s biggest publicly traded health-care provider, said Friday that it’s in talks to buy US generic drugmaker Akorn.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    While discussions are under way, there’s no certainty of a deal, said Fresenius, a maker of dialysis and medical products. The Germany-based company didn’t elaborate in a statement about the talks and a spokeswoman for Akorn declined to comment.

    Akorn could complement Fresenius’s Kabi medicines division, which specializes in intravenous drugs, and accounts for about a fifth of the company’s revenue. Sturm said in February that the company could look at small-to-medium sized acquisitions to build up the business, and didn’t rule out larger deals.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.